Q3: 2025-11-04 Earnings Summary
EPS of $0.20 beats by $0.08
| Revenue of $205.63M (4.59% Y/Y) beats by $5.62M
Orthofix Medical Inc. (OFIX) UBS Global Healthcare Conference 2025 November 11, 2025 1:15 PM EST
Company Participants
Massimo Calafiore – President, CEO & Director
Julie Dewey – Chief Investor Relations & Communications Officer
Conference Call Participants
Danielle Antalffy – UBS Investment Bank, Research Division
Presentation
Danielle Antalffy
UBS Investment Bank, Research Division
All right. Good afternoon, everyone. Thank you for joining us. I’m Danielle Antalffy, I’m the U.S. med tech analyst here at UBS. Very honored to have with us Orthofix Medical. We have President and CEO, Massimo Calafiore. We have Chief — well, we don’t have the Chief Financial Officer, reading off that. We have Julie Dewey, Head of Investor Relations. Unfortunately, Julie Andrews, Chief Financial Officer, could not make it because of travel issues. But I think we got it covered with the folks on this stage.
Question-and-Answer Session
Danielle Antalffy
UBS Investment Bank, Research Division
So Massimo, maybe give a minute or two or five, whatever you need, to give a quick overview of the business for folks that might not be as familiar with Orthofix?
Massimo Calafiore
President, CEO & Director
So Orthofix is a med tech company focused on the spine — on the spine market on both Bone Growth Therapy market, Biologics and Orthopedics. We are a pretty competitive portfolio. We joined — we started this journey 2 years ago. And — with the idea in mind to make sure that we would — to utilize all the commercial synergies that we could of the portfolio that we had while at the same time, funding specific pocket within this broad market where we compete where we can win, but with, in mind, this idea of profitable growth and free cash flow creation.
So in the Spine vertical, we are still subscale, but a pretty strong portfolio
Read the full article here
